Human Genome Sciences, Inc.

Abbott Biotechnology Ltd.

Cambridge Antibody Technology Limited

Medimmune Limited

Basf Aktiengesellschaft

Medical Research Council

Abbvie Biotechnology Ltd

Tristan J Vaughan

Alison Jane Wilton

Boris Labkovsky

Jochen G Salfeld

Zehra Kaymakcalan

Michael White

Brian Timothy McGuinness

Paul Sakorafas

John A Mankovich

David Schoenhaut

Deborah J Allen

Andrew J Roberts

Steven M Ruben

Hendricus R J M Hoogenboom

Gil H Choi

David M Hilbert

Stephen Smith

Sarah Helen Main

Kevin Stuart Johnson

John Gerald McCafferty

Elaine Joy Derbyshire

Jane Katharine Osbourn

Craig A Rosen

Claire Louise Dobson

Vivian Albert

Theodora W Salcedo

Steven C Barash

Brian T Mcguinness

Gregory Paul Winter

Philip Ronald Tempest

David C Lowe

Ronald Henry Jackson

Andrew James Williams

Hendricus Renerus Hoogenboom

Julia Elizabeth Thompson

James Button

Jonathan Alexander Green

Louise Bacon

Raymond Paul Field

Steven Paul Ruddock

Stacey Chin

Benjamin David Grimshaw

Hendricus Rjm Hoogenboom

Alison J Wilton

Hendricus R Hoogenboom

Boris Labkovksy

Hendricus RJM Hoogenboom

Brian T Mcguiness

The present invention relates to a library (in particular a phage display library) from which an improved human antibody having greater specificity and potency for its target may be generated; and to methods of generating such a human antibody. In particular, the invention relates to a human antibodies against challenging targets obtainable from such a library and which have HCDR3s of at least 18 amino acids in length.

Phage display library, members thereof and uses of the same

Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-213/-213 VH and/or VL domains especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment or the human or animal body by therapy.

Human antibodies against eotaxin and their use

Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.

Methods of obtaining a specific binding member that binds eotaxin

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Antibodies that immunospecifically bind to B lymphocyte stimulator protein

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&#x3b1;

Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.

Human antibodies that bind human TNF&#x3b1; and methods of using same

Methods of treating disorders using human antibodies that bind human TNF&#x3b1;

Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa

Antibodies that immunospecifically bind to B lymphocyte stimulator

Growing community of inventors

Impington, United Kingdom

Tristan J Vaughan